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1. Introduction 
Antiplatelet therapy with clopidogrel (Plavix) is now considered a cornerstone of 
cardiovascular medicine. Clopidogrel resistance is an emerging clinical entity with potentially 
severe consequences such as recurrent myocardial infarction (MI), stroke, or death. Since its 
initial description, multiple investigators have confirmed the phenomenon of clopidogrel 
resistance (Dziewierz et al., 2005; Gurbel & Tantry, 2007; Mega et al., 2009; Mobley et al., 2004; 
Müller et al., 2003). The prevalence of clopidogrel non-responsiveness has been reported at  
5–44% in other populations (Gurbel & Tantry, 2007). Although the occurrence of clopidogrel 
resistance is multi-factorial, it has been associated with a CYP2C19- and PON1-mediated1 
patient’s metabolic inability to generate sufficient active metabolite to arrest platelet reactivity. 
Rapid and accurate detection of clopidogrel resistance in Hispanic Puerto Rican patients 
remain unsolved as new bedside genetic tests are developed.  
In a recent GWAS analysis, it was estimated that up to 83% of individual variance in response 
to clopidogrel might be attributable to genetic effects (Shuldiner et al., 2009), but the gene 
variants investigated thus far explain only a minor proportion of such response variability 
(Holmes et al., 2010; Hulot et al., 2010). The high heritability of clopidogrel response but 
relatively weak prediction by existing proposed genetic markers argues for the involvement of 
some as yet undiscovered genetic factors. The CYP2C19*2 allele was reported to account for 
only 12% of the variability in ADP-stimulated platelet response to clopidogrel (Shuldiner et al., 
2009). The PON1 Q192R polymorphism explained 72.5% of clopidogrel response variability in 
individuals of European ancestry (Bouman et al., 2011). However, a previous GWAS in a 
cohort of related healthy subjects of Amish descent provided no evidence for an association of 
the PON1 gene region with the platelet response to clopidogrel (Shuldiner et al., 2009). 
Due to its remarkable heterogeneity and trichotomous ancestral genetic admixture, the 
Puerto Rican population may significantly differ from other earlier pharmacogenetically 
                                                 
1 CYP2C19 stands for Cytochrome P450 isoform 2C19 (family 2, subfamily C, polypeptide 19) gene; 
PON1 stands for Paraoxonase 1 gene.  
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characterized populations with respect to the frequency, distribution and combination of 
allelic variants in genes associated with drug response and diseases (González-Burchard et 
al., 2005; Suarez-Kurtz et al., 2006). We have published a physiogenomic analysis to infer 
structure and ancestry in the Puerto Rican population. The Puerto Rican sample was found 
to be broadly heterogeneous, with three main clusters reflecting the historical admixture 
from Taino Amerindians, West-Africans, and Iberian European ancestors (Ruaño et al., 
2009). Our results matched previously published estimations of Puerto Rican admixture that 
were ascertained using more traditional ancestral genetic markers (Bertoni et al., 2003; 
Bonilla et al., 2004a, 2004b; Choudhry et al., 2006; Hammer et al., 2006; Hanis et al., 1991; 
Martinez-Cruzado et al., 2001, 2005). The study provided a set of 384 physiologically 
informative SNPs from 222 cardio-metabolic and neuro-endocrine genes that can be used to 
facilitate the translation of genome diversity into personalized medicine and control for 
admixture in Puerto Ricans. The observed large variance in admixture proportions 
suggested that this population is ideal for admixture matching studies. 
Admixture is of great relevance to the clinical application of pharmacogenetics and 
personalized medicine, but unfortunately these studies have been scarce. As 
physiogenomic-guided multi-gene models are developed to predict drug response, the 
range of possible allelic combinations in the Puerto Rican population is certain to exceed 
that in populations without admixture. In addition, the allele frequencies for both the 
CYP2C19 and PON1 candidate genes in this population have not been fully characterized. 
Accordingly, we investigated whether a correlation between overall genetic similarity and 
CYP2C19 and PON1 genotypes could be established in the study population. This chapter 
also provides valuable evidence on the importance of controlling for admixture in 
pharmacogenetic studies of admixed populations like Puerto Ricans. Indeed, we will discuss 
how known or cryptic population stratification can have a strong confounding effect on 
further clinical association analysis. Finally, the necessity to utilize results of our admixture 
analysis to parameterize population structure appropriately and account for it as a covariate 
in the corresponding association studies will also be considered. 
2. Methods 
2.1 Specimens  
100 human genomic DNA samples (40-60 ng/μL) were extracted and purified from existing 
dried blood spots on Guthrie cards supplied by the Puerto Rico Newborn Screening 
Program (PRNSP), where >95% of Puerto Rican newborns are screened for common 
hereditary diseases. Accordingly, sample analysis in this survey (protocol #A4070107) was 
exempt from IRB review under FDA and OHRP guidelines based on category 4, 
45CFR46.118. A controlled stratified-by-region random sampling protocol was followed, 
taking into consideration the percentage of birth at each region across the Island of Puerto 
Rican based on the 2004 national register of total births. Two samples were discarded from 
final analysis due to poor quality. 
2.2 Array 
The extracted genomic DNA samples were genotyped on a physiogenomic (PG) array 
detecting 384 SNPs from 222 cardio-metabolic and neuro-endocrine genes spanning their 
entire genome (Ruaño et al., 2005a; Ruaño & Windemuth, 2006). Since the PG-array was 
constructed such that it covers all common variations in the general population for 
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pharmacologically relevant cardio-metabolic pathways, virtually any set of candidate 
genes within these pathways can be tested from the resulting dataset without any further 
assay. Consequently, genotypes associated with the clinically relevant CYP2C19*2 
(rs4244285; splicing defect G681A SNP) and nonsynonymous PON1 (rs662; p.Q192R) 
polymorphisms were loaded from the derived database. Instead, array translation was 
used to impute genotyping related to CYP2C19*3 (rs4986893; stop codon G636A SNP) 
with high accuracy, given its strong linkage disequilibrium with SNP rs3758581. Wild-
types were assigned as a result of the absence of such SNPs. The PG array has been tested 
on nearly 5,000 patients and has been successfully applied in cardiovascular and 
neuropsychiatric pharmacogenetic research, resulting in ten publications (de Leon et al., 
2008; Liu et al., 2009; Ruaño et al., 2005b, 2007a, 2007b, 2008, 2009, 2010; Seip et al., 2008; 
Windemuth et al., 2008). Careful manual analysis was performed on the alignments 
underlying the genotype calls using GenCall 6.1.3.24 and 50 SNPs with even a slight 
degree of uncertainty about calling accuracy were not included in the analysis, leaving 
332 SNPs from 196 genes. Genotyping was accomplished using Illumina® BeadArrayTM 
technology (Oliphant et al., 2002).  
2.3 Clustering and statistical analysis  
Analysis of the results using the STRUCTURE v2.2 software package was used to cluster 
those subjects with similar genetic profiles (Falush et al., 2007; Pritchard et al., 2000). 
Hierarchical clustering algorithm was blind as to ethno-geographic ancestry. A detailed 
explanation of the analytics underlying the clustering of the samples and the hierarchical 
stratification by allelic dissimilarities to infer population structure, as well as a full list of the 
genes and SNPs in the PG array, is provided elsewhere in our physiogenomic analysis study 
(Ruaño et al., 2009). Allele frequencies, f, linkage disequilibrium (LD), and haplotype 
structure were individually determined for all loci. Wright’s F-statistic was calculated for 
each locus from the observed total heterozygosity HT=Nhz/N and the subpopulation 
heterozygosity HS=2f·(1-f), assumed under Hardy-Weinberg equilibrium (HWE), as FST=(HT-
HS)/HT. A t-test was performed to see whether the average Fst across all loci is different from 
zero. Departure from HWE were estimated under the null hypothesis of the predictable 
segregation ratio of specific matching genotypes (p>0.05) by use of χ2 goodness-of-fit test 
with one degree of freedom. In addition, χ2 test was also used to compare observed allele 
frequencies within each sector in the corresponding dendrogram with expected frequencies 
given the overall allelic ratios, at 5% of significance. 
3. Results 
Results are presented in Table 1, and graphically in Figure 1 by hierarchical dendrograms to 
illustrate the population structure as represented by allelic dissimilarity (i.e., genetic 
distance). There appear to be three main sectors, from left to right: PR126–PR341; PR321–
PR69 and PR97–PR175. There are also two smaller sectors between the three main sectors. 
One pair of samples (PR26 and PR92) shows an unusually low allelic dissimilarity, 
suggesting relatedness. However, due to anonymousness of collected samples, we were 
unable to further investigate this issue. Those individuals who shared many polymorphisms 
were grouped together in one “sector” while those with whom they had much more genetic 
dissimilarities lie on the other side of the “phylogenetic tree’ map; thus greater distances 
denoting lesser degrees of common ancestry.  
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Gene SNP Ch Location Na Allelesb 
MAF 
(%) 
Genotypes 
Fst 
WT HET MUT 
CYP2C19 
rs4244285 
(CYP2C19*2) 
10 96541616 98 GA 14.8 52 17 2 0.042 
CYP2C19 
rs3758581 
(CYP2C19*3) 
10 96602623 95 GA 3.5 66 5 0 0.017 
PON1 rs662 7 94937446 96 
AG 
(T/C) 
45.1 22 34 15 0.174 
Table 1. Genes, allele and genotype frequency distributions of clopidogrel-associated 
polymorphisms in the representative sample of Puerto Ricans analyzed by PG-array. Ch 
column display the chromosome on which the SNP can be found. Location column contains 
the chromosome location for each SNP given by the NCBI Entrez SNP database, build 36.3 
reference assembly. MAF stands for minor allele frequency. aTotal number of samples 
analyzed by PG-array ranged between 95 to 98. However, only 71 samples were used for 
STRUCTURE clustering analysis due to incomplete combinatorial genotyping data. Only 
those samples having a strong association with one of the three clusters were finally 
included in the superimposition analysis. bAncestral allele in bold. First allele is the 
reference one. 
To determine if there are relationships between genetic clusters defined by STRUCTURE 
analysis and clopidogrel-related genotypes, we superimposed the individual genotypes for 
CYP2C19 and PON1 on the dendrogram. Figures 1, panel A and B, show less than 98 cases 
(i.e., some lanes in the genetic distance map do not have identified ancestry) due to incomplete 
combinatorial genotyping data during the initial PG array analysis or because the individual 
residing in the site did not meet a categorical criterion of proximity (> 0.20), which precluded 
definitive assignment to any of the three STRUCTURE clusters (ancestry). Furthermore, only 
those samples having a strong association with one of the three clusters were included in the 
superimposition analysis, yielding 71 total subjects. Notice that only 52 out of these 71 
analyzed cases were actually located within any of the three identified sectors in the genetic 
distance dendrograms seen in Figures 1. The other 19 cases, although located outside the 
sectors, were also included in the analysis because they all had a significant contribution from 
one of three ancestries (i.e., Taino Amerindians, Iberian Caucasians or West-Africans), as 
denoted by their ancestral coefficients. To this purpose, each of these 19 individual was 
allocated to the sector that best matched with his/her greater ancestral coefficient. The 
distribution of samples by sectors in the corresponding genetic distance dendrograms was 
then as follows: 20 samples in sector 1; 27 in sector 2 and 24 in sector 3.  
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Fig. 1. Panel A. Individual CYP2C19*2 and *3 genotypes overlaid on the genetic distance 
dendrogram for the samples from the Puerto Rican population (dendrogram taken from 
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previously published physiogenomic population analysis [21]). Green boxes are depicting 
those individuals having a single CYP2C19*2 polymorphism (G/A); Blue-colored boxes 
represent double carriers for CYP2C19*2 (A/A); whereas, purple-colored rectangles indicate 
single carriers of CYP2C19*3 (A/G). Double-colored rectangle (subject PR224) highlights the 
one having the *2/*3 genotype. The CYP2C19*3 G→A polymorphism is in high linkage 
disequilibrium with rs3758581, which has been associated with a significant decrease in 
clopidogrel activation per allele and, therefore, resistance phenotype (non-responder) to 
standard dose. Panel B: Individual PON1 Q192R genotypes overlaid on the genetic distance 
dendrogram for the samples from the Puerto Rican population. Yellow color represents 
single carriers; purple color denotes double carriers of this polymorphism (G allele). p-
values were calculated by a χ2 test comparing observed allele frequencies with expected 
frequencies given the overall allelic ratios. 
By previous STRUCTURE clustering analyses, the dendrogram sectors 1, 2 and 3 in Figure 1 
correspond to Taino Amerindian, Iberian Caucasian, and West-African heritage, respectively 
(Ruaño et al., 2009). Indeed, sector 1 bears a concentration of samples assigned to cluster 2 
(Amerindians) in the STRUCTURE plot. Sector 2, in the middle, is disproportionately rich in 
samples corresponding to cluster 3 (Europeans). Sector 3, to the right, is clearly enriched with 
cluster 1 samples (Africans). For the 71 cases with complete genotypes, the CYP2C19*2 allele 
frequency was 14.8%, whereas the *3 allele frequency was 3.5%. Although slightly higher, 
these findings are consistent with early reports in 22 Latin Americans (Mexicans and Puerto 
Ricans) from the 1,000 Genomes Phase I selection, where the CYP2C19*2 and *3 minor allele 
frequencies were 13.6% and 1.7%, respectively. Regarding to CYP2C19*2 polymorphism, we 
identified 52 homozygous for the wild-type allele G, 17 heterozygous and 2 double carriers of 
the variant allele A. However, the analysis for CYP2C19*3 revealed 66 wild-types, 5 single 
carriers of the variant allele, but none double carrier of this polymorphism in the study 
population. Sectors 1 and 3 in Figure 1, panel A, show CYP2C19*2 allele frequencies of 10% (4 
out of 40) and 4.16% (2 out of 48), respectively, as compared to 27.8% (15 out of 54) in sector 2. 
Statistical analyses to compare each sector to the overall allelic ratios, revealed that sector 2 (in 
the middle of the genetic distance dendrogram, Figure 1-panel A), showed a frequency of 
CYP2C19*2 that was 4-fold higher than the rest of the population (p=0.0016). Likewise, carrier 
prevalence in sector 2 (48.15%) was significantly greater than that observed in the other two 
sectors (i.e., 20 and 8.3%, respectively). 
Sector 2 is associated with Iberian European heritage (Ruaño et al., 2009). According to the 
HapMap project dataset (International HapMap Consortium, 2005), the minor allele 
frequency for CYP2C19*2 is 14.3% in 223 Caucasians who are Utah residents with Northern 
and Western European ancestry from the CEPH collection (HapMap-CEU; data release#28, 
Phase II + III). Similarly, the CYP2C19*2 allele frequency was 13% for 261 Europeans in the 
1,000 Genomes Phase I selection (Amigo et al., 2008). The present study reports a relatively 
inflated minor allele frequency of 27.8% for the CYP2C19*2 variant in sector 2 (primarily 
Caucasian), consistent with the possible interpretation that Puerto Ricans in this sector 
reflect an increased admixture with Asians (i.e., Taino Amerindians). The link between 
Amerindians and Asians originates with the “Bering Strait” theory (Jennings, 1979). 
According to previous reports, there seems to be a very high frequency for the CYP2C19*2 
variant in East Asian populations, ranging from 27-32.5% (Amigo et al., 2008).  
Likewise, the observed minor allele frequency of 4.16% in sector 3 is lower than expected for 
a population of purely African ethno-geographic origin, no surprise given the heterogeneity 
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of the Puerto Rican population. The reported CYP2C19*3 allele frequencies of 5% for sector 
1, 3.7% for sector 2 and 2.1% for sector 3 compare to the expected HapMap values of 5.6%, 
1.7% and 0.3%, respectively. The higher than expected frequencies observed in sector 2 and 
3 seem to be a direct consequence of significant admixture with Asian ancestry in 
individuals assigned to these clusters. Interestingly, the NCBI webpage reports a CYP2C19*3 
minor allele frequency of 2.1% in 24 individuals of self-described African-American heritage 
(AFR1, SNP500Cancer project, this database is an integral component of the NCI Cancer 
Genome Anatomy Project, available at http://cgap.nci.nih.gov), which is a population with 
certain genetic admixture (Packer et al., 2006). This value matched the observed allele 
frequency in sector 3, a cluster of majorly African ancestry. 
With respect to the PON1 gene (Table 1), the overall allele frequency was 45.1% (34 
heterozygous and 15 homozygous for the variant allele), which is stratified by clusters as 
42.5%, 38.9% and 54.2% in sectors 1, 2 and 3, respectively (Figure 1-Panel B). The observed 
prevalence for this variant is consistent with early reports in both 22 Latin America 
inhabitants (Mexicans and Puerto Ricans; 1,000 Genomes Phase I selection) and 58 Mexican 
descendants who reside in Los Angeles, California (HapMap-MEX; HapMap project dataset, 
release#28, Phase II + III), where the PON1 minor allele frequencies were estimated to be 
47.7% and 50%, respectively. The minor allele frequency in the general population ranges 
from 42.2 to 47.9%. However, when comparing observed allele frequencies in each of the 
three sectors (i.e., 1=Amerindian; 2=Caucasian; 3=West African) with the HapMap and 1,000 
Genomes Phase I project values, the results are showing a significantly higher than expected 
prevalence of this PON1 polymorphism. In sector 1, there was a minor allele frequency of 
42.5% as compared with the HapMap report of about 36% for the Han Chinese of Beijing 
(International HapMap Consortium, 2005) and the 36.2% in East Asians from 1,000 Genomes 
Phase I selection (Amigo et al., 2008).  
Furthermore, the allele frequency in sector 2 was 38.9% (13 heterozygous and 4 double 
carriers), considerably higher than the reported 29% for Caucasian residents of Utah, 
documented in the HapMap database (International HapMap Consortium, 2005), and the 
28.4% presented by the 1,000 Genomes Phase I selection for Europeans (Amigo et al., 2008). 
Additionally, in sector 3 the allele frequency was 54.2% (12 heterozygous and 7 double 
carriers), which is by far a higher prevalence versus the HapMap allele frequency of 27.9% 
for the Nigerian YRI population or the 23.4% in Africans of the 1,000 Genomes Phase I 
selection (Amigo et al., 2008; International HapMap Consortium, 2005). Statistical analyses 
to compare each sector to the overall allelic ratios, revealed that sector 3 (right-most portion 
of the genetic distance dendrogram, Figure 1-panel B), showed a frequency of PON1 Q192R 
that was only marginally different than the rest of the population (p=0.047). 
Greater admixture and heterogeneity in the Puerto Rican population as compared to the 
African-American population or certainly the Yoruba population allow for the presence of 
the twenty-six PON1 variant allele observed in the twenty-four individuals in sector 3 
(Figure 1-Panel B) to have come from partial Amerindian ancestry, as no individual in that 
sector was of purely West-African descent (Ruaño et al., 2009). The observed trends may 
also be an artifact of chance given the relatively small sample size. No statistically significant 
deviations from HWE were found with respect to the distribution frequencies of either 
PON1 or CYP2C19 polymorphisms. Since no departures from HWE were observed and 
considering that our study cohort is island-wide, chosen by a controlled, stratified-by-
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region, representative sampling from the Puerto Rican population, we can expect the 
observed frequencies of the PON1 and CYP2C19 polymorphisms to be representative for the 
rest of this population. 
4. Discussion 
In this work, we examined two clinically relevant CYP2C19 gene polymorphisms (i.e., 
CYP2C19*2 and CYP2C19*3) and the emerging PON1 variant in a representative sample of 
the Puerto Rican population. Our findings suggest a significant burden of loss-of-function 
CYP2C19 and PON1 carriers within the Puerto Rican population. Based on observed 
prevalence of functional CYP2C19 and PON1 polymorphisms in Puerto Ricans, and the 
postulated role of the enzymes encoded by these genes in the clopidogrel activation 
(Bouman et al., 2011; Mega et al., 2009; Shuldiner et al., 2009), we hypothesized that about 
30-40% of Puerto Ricans may be non-responders to clopidogrel and such resistant patients 
may be at particular risk for short-term thrombo-ischemic complications including 
periprocedural infarction and early stent thrombosis. 
Because thromboembolism is a major risk of cardiovascular disease, genotyping for 
clopidogrel’s response-associated gene CYP2C19, and PON1 to a lesser extent, have been 
advanced as desirable in Caucasians to improve patient’s clinical outcomes (Bouman et al., 
2011; Holmes et al., 2010; Hulot et al., 2010; Mega et al., 2009; Shuldiner et al., 2009). 
However, heterogeneity and admixture may preclude their full application in other 
populations such as Puerto Ricans. Accordingly, there is an urgent need for ascertaining 
admixture adjustments that may prove clinically useful in Puerto Ricans and other Hispanic 
groups. Indeed, the richer genetic variation in Puerto Ricans is likely to contribute 
substantially to a wider variation in response to clopidogrel treatment, a component that 
will be missed by traditional studies in homogeneous populations. This addressable 
oversight is of great concern, since it will tend to exacerbate the healthcare disparity already 
experienced by Hispanics in USA. 
The population of the Americas carries a genomic legacy resulting from the continents’ 
native inhabitants, European colonization and African slavery. In those parts of the 
Americas where admixture took hold, the populations manifest the combined 
anthropological heritage in their genomes, lifestyle, diet, and even socioeconomic status. 
Admixture is of great relevance to the clinical application of the pharmacogenetic-guided 
personalized medicine paradigm, but unfortunately these studies have been scarce in Puerto 
Ricans. We have performed pivotal physiogenomic studies on the Puerto Rican population 
by using an array of 384 SNPs in 222 cardio-metabolic and neuro-endocrine genes coding for 
relevant pharmaceutical targets. According to our findings, the Puerto Rican population 
represents different admixtures of 3 major ethno-geographic groups (i.e., Taino-
Amerindians, Iberian-Europeans and West-Africans). Notably, each subject in the study 
population was a ‘genetic mosaic’, with contributions from each of these three clusters, but 
in widely different proportions.  
Consequently, admixture in the Puerto Rican population exists in the form of a continuous 
gradient with varying levels of mixture that results in a rich repertoire of combinatorial 
genotypes for key pharmacological pathways such as the one associated with CYP2C9 and 
PON1 activity in humans. This phenomenon may explain discrepancies between observed 
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and expected genotype and allele frequencies across the three sectors in the genetic distance 
dendrograms (Figure 1-panel A and B), particularly with respect to other homogeneous 
(parental) populations previously characterized through the HapMap, SNP500Cancer and 
1,000 Genomes projects. Moreover, the diversity observed in the genetic structure within 
African populations from varying regions of this continent (Tishkoff et al., 2009) may also 
contribute to explain the higher than expected prevalence of PON1 variant allele at sector 3 
(Figure 1-panel B) in our study population, which is an Afro-Caribbean population, as 
compared to continental Africans like Yoruba from Nigeria (HapMap-YRI). Overall, our 
findings further substantiate the argument for including admixture as a critical covariant in 
predicting clopidogrel response within heterogeneous populations, but also render the 
Puerto Rican population a good resource to develop DNA-guided systems for clinical 
management of thromboembolic disorders, an urgent medical need not only in Hispanics 
but also in the population at large.  
Recently, we provided valuable evidence on the importance of controlling for admixture 
when conducting pharmacogenetic studies of warfarin (Coumadin) in the Puerto Rican 
population and stressed the argument for incorporating admixture-matching in order to 
probe variations in warfarin response across different stratum within the population 
(Villagra et al., 2010). In this study we postulated that interindividual variations in 
ancestral contributions of Puerto Ricans may help explain the observed poor performance 
and low predictability of DNA-guided warfarin dosing algorithms derived in other 
populations. Admixture introduces distinct levels of population sub-structure or stratum, 
with marked variations in individual ancestry among the members of a particular 
population or ethnic group, depending on the dynamics of the process. Accordingly, any 
extrapolations of clinically relevant pharmacogenetic data from non-admixed to admixed 
groups will be plagued with uncertainty as exemplified by Suarez-Kurtz (Suarez-Kurtz, 
2005). Consequently, the predictive power of previously published DNA-guided 
algorithms for admixed populations like Puerto Ricans is expected to be inaccurate, if not 
inadequate. 
A previous study by Perini and co-workers (Perini et al., 2008) stated that self-reported race, 
using labels defined by skin color as a proxy for ethnicity, was not a reliable indicator of 
effective anticoagulation therapy in admixed Brazilians. What proved useful, instead, was a 
precise knowledge of individual ancestral proportions so as to place the patient on a 
continuum between “black” and “white”. The utility of this model was verified later on a 
separate cohort in the same population (Vargens et al., 2008). To control for possible 
marginal effects of ancestry on drug response, investigators of the GALA and SAGE projects 
included genetic ancestry as an independent variable in the regression model used to test 
association between IL6R SNPs and bronchodilator effect. Interestingly, the mean 
bronchodilator response for the pharmacogenetic interaction increased with increasing 
amounts of Native American ancestry; whereas, the drug response among asthmatic 
patients for the same pharmacogenetic interaction decreased with increasing amounts of 
European ancestry (Corvol et al., 2009). Differences observed among Mexican, Puerto Ricans 
and African-Americans were thus explained by the different proportions of Native 
American and European ancestries in these three ethnically diverse populations. Recently, 
Bryc and co-workers found evidence of a significant sex bias in admixture proportions of 
Hispanics that is consistent with disproportionate contribution of European male and 
Amerindian or African female ancestry to present populations (Bryc et al., 2010). These 
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authors also suggested that future genome-wide association studies in Hispanics will 
require correction for local genomic ancestry at a sub-continental scale. 
Population stratification by admixture is a well-known confounder in pharmacogenetic 
association studies of candidate gene to complex traits, including drug response (e.g., 
clopidogrel). In this context, it might be difficult to find a matching control for an individual 
with diverse ethnic origins; therefore, we will be forced to rely on multivariate adjustment 
models. That is, rather than allocate the subject to a single stratum in the analysis, we 
recommend to construct a covariate for each stratum, giving the corresponding ancestral 
proportion derived from our admixture-driven clustering analysis, and then include these 
covariates as adjustment factors in a multiple regression model for clopidogrel association 
studies in Puerto Ricans. In doing so, we will be able to parameterize admixture-derived 
population structure appropriately and account for it as a covariate in the corresponding 
association studies in order to minimize the effect of population stratification.  
We call these covariates “admixture indexes”, which we believe are indispensable to assure 
that pharmacogenetic research can be pursued in Hispanic populations. From a key 
methodological perspective, the wider genetic variation found in our population for these 
markers broaden the reach and enhance the statistical sensitivity of tests for the effects of 
that variation on clopidogrel response. At the same time, the admixture index could become 
indispensable for the globalization of patho- and pharmacogenetic research beyond the 
Americas, to Africa, Asia and Europe, the continents whose populations contributed to the 
admixture in the first place. 
In the context of admixture matching, if a resistant allele is more common in one of the 
ancestral populations, then non-responders to clopidogrel will share a greater level of 
ancestry from that population around the locus as compared with responders. In future 
studies, we expect to generate a detailed admixture map in the Puerto Rican population at 
very high resolution using all 1.2 million SNPs from a total genome (TG) array. Admixture 
studies at this resolution afford delineation of candidate genes for pharmacogenetic traits 
related not only to clopidogrel, but also to other drugs commonly used to treat 
cardiovascular conditions of high prevalence in Hispanics. 
A major advance in healthcare would be a transition from the current empirical approaches 
in drug therapy to a genetically predictive framework for determining the individual 
patient’s response to medicines. Accordingly, an understanding of how human genetic 
diversity and admixture in Hispanics is structured is not only of anthropological 
importance, but also of medical relevance. In addition, it is important to recognize that some 
minority groups in the U.S. (e.g., Hispanics) might be underrepresented in typical clinical 
pharmacogenetic trials with respect to the real impact of these groups on the current U.S. 
population. Because of the heterogeneity and extensive admixture of the Puerto Rican 
population, extrapolation on a global scale of data derived from well-defined ethnic groups 
(i.e., Caucasians) is clearly not applicable to the majority of Puerto Ricans. 
5. Conclusion 
In conclusion, we have established clinical correlations between overall genetic similarities 
and both CYP2C19 and PON1 genotypes in a representative sample of the Puerto Rican 
population. To this purpose, the major CYP2C19 and PON1 polymorphisms were 
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interrogated in 98 genomic DNA specimens using the physiogenomic (PG)-array that also 
inferred population structure and admixture pattern. Individual CYP2C19 and PON1 
genotypes were visually overlaid atop three major sectors of a genetic distance dendrogram 
that was constructed by clustering subjects with similar genetic profiles. Results suggest that 
the observed inter-individual variations in ancestral contributions will have significant 
implications for the way each Puerto Rican responds to antiplatelet therapy with 
clopidogrel. Our findings also provided valuable evidence on the importance of 
parameterizes the population structure in order to account for admixture as a covariate in 
pharmacogenetic association studies for clopidogrel in Hispanic Puerto Ricans. 
Rather than ignoring admixture, pharmacogeneticists should consider it as starting point for 
better understanding the underlying basis of the observed wider variability in drug 
responses among patients of mixed populations. Such understanding provides the 
opportunity to develop strategies for leapfrogging the healthcare standards in these 
populations. 
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